Interleukin-35: Immunosuppressive mechanisms in cancer and autoimmune diseases
Gökçen Kılınç1
, Oytun Erbaş2
1University of George Emil Palade, Faculty of Medicine, Târgu Mureș, Romania
2Institute of Experimental Medicine, Gebze-Kocaeli, Türkiye
Keywords: Autoimmune disease, cancer, IL-35, immunosuppression.
Abstract
Interleukin-35 (IL-35) causes cancer to become more tumorigenic, prevents cancer cells from dying, and accelerates the spread of the disease. Cancer is a significant cause of morbidity and mortality and is one of many side effects of immunosuppressants. The increasing use of immunosuppressants in non-transplant patients especially helps define the effect of mild to moderate immunosuppression more precisely. This review examined the relationship between IL-35 immunosuppression, cancer, and autoimmune diseases, and the new types of diseases it creates.
Cite this article as: Kılınç G, Erbaş O. Interleukin-35: Immunosuppressive mechanisms in cancer and autoimmune diseases. D J Tx Sci 2024;9(1-2):1-9. doi: 10.5606/ dsufnjt.2024.18.
Writing-original draft preparation, writing-review and editing, data collection, methodology: G.K.; Control/supervision: O.E.
The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
The authors received no financial support for the research and/or authorship of this article.
Data Sharing Statement:
The data that support the findings of this study are available from the corresponding author upon reasonable request.